|
Dr. Koppán Miklós publikációs listája (2008. április 27.) (kumulatív impakt faktor: 166,227) 1. Szabo I, Koppan M, Bodis J. Antenatal steroid treatment: suppression with no impairment of the adaptive function of the HPA-axis in newborns at birth. Am J Obstet Gynecol. 2008 Mar 21; [Epub ahead of print] 2. Varnagy A, Koppan M, Manfai Z, Busznyak C, Bodis J. Low-dose aspirin for prophylaxis of ovarian hyperstimulation syndrome. Fertil Steril. 2008 Apr;89(4):1035-6. 3. Kriszbacher I, Boncz I, Koppán M, Bódis J. Seasonal variations in the occurrence of acute myocardial infarction in Hungary between 2000 and 2004. Int J Cardiol. 2007 Nov 14; [Epub ahead of print] 4. Zámbó K, Szabó Z, Schmidt E, Koppán M, Répásy I, Bódis J. Is the clinical staging system a good choice in the staging of vulvar malignancies? Eur J Nucl Med Mol Imaging. 2007 Nov;34(11):1878-9. 5. Verzár Z, Kövér E, Dóczi T, Kálmán E, Koppán M, Bódis J. Successful treatment of FIGO stage IV gestational choriocarcinoma occurring 2 months after delivery. Eur J Obstet Gynecol Reprod Biol. 2007 May 21; [Epub ahead of print] 6. Betlehem J, Koppán M, Bódis J. Optimal range of hemoglobin concentration in pregnancy. Am J Obstet Gynecol. 2006 Nov;195(5):1499-500. 7. Németh K, Koppán M, Zámbó K, Bódis J. Prophylactic oophorectomy in patients with increased risk of ovarian cancer. Am J Obstet Gynecol. 2005 Oct;193(4):1580. 8. Schmidt E, Anga B, Koppán M, Bódis J, Zámbó K. Effectiveness of 99mTc-MIBI SPECT-scintimammography at patients with suspicion of breast cancer in relation to mammographic density. Maturitas. 2006 Jan 10;53(1):119-20. 9. Garai J, Molnar V, Varga T, Koppan M, Torok A, Bodis J. Endometriosis: harmful survival of an ectopic tissue. Front Biosci. 2006 Jan 1;11:595-619. Review. 10. Kriszbacher I, Ajtay Z, Koppán M, Bódis J. Can the time of taking aspirin influence the frequency of cardiovascular events? Am J Cardiol. 2005 Aug 15;96(4):608-10. 11. Kriszbacher I, Koppán M, Bódis J. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Jul 28;353(4):429-30. 12. Bódis J, Koppán M, Németh K. Efficacy of radiotherapy for ovarian ablation; results of a breast intergroup study. Cancer. 2005 Jul 1;104(1):220; author reply 220-1. 13. Kriszbacher I, Koppán M, Bódis J. Would it be more beneficial to take aspirin in the evening for prevention of cardiovascular diseases? J Vasc Surg. 2005 Feb;41(2):375. 14. Kriszbacher I, Koppán M, Bódis J. Aspirin for stroke prevention taken in the evening? Stroke. 2004 Dec;35(12):2760-1. 15. Koppan M, Bodis J, Verzar Z, Tinneberg HR, Torok A. Serotonin may alter the pattern of gonadotropin-induced progesterone release of human granulosa cells in superfusion system. Endocrine. 2004 Jul;24(2):155-9. 16. Garai J, Világi S, Répásy I, Koppán M, Bódis J. Short communication: seasonal onset of menopause? Hum Reprod. 2004 Jul;19(7):1666-7. 17. Zámbó K, Koppán M, Paál A, Schmidt E, Tinneberg HR, Bódis J. Sentinel lymph nodes in gynaecological malignancies: frontline between TNM and clinical staging systems? Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):1684-8. Review. 18. Bódis J, Koppán M, Garai J, Zámbó K, Török A. Issues to debate on the Women's Health Initiative: estrogen: an instrument or the conductor of the orchestra? Hum Reprod. 2003 Aug;18(8):1561-3. 19. Zámbó K, Koppán M, Bódis J. Is sentinel lymph node investigation useful for early tumour stages only? Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1544. 20. Bódis J, Koppán M, Kornya L, Tinneberg HR, Török A. The effect of catecholamines, acetylcholine and histamine on progesterone release by human granulosa cells in a granulosa cell superfusion system. Gynecol Endocrinol. 2002 Aug;16(4):259-64. 21. Török A, Belágyi J, Németh P, Berki T, Török B, Bódis J, Koppán M. Oxidative stress may have an influence on the effectiveness of IVF. Hum Reprod. 2002 Oct;17(10):2779-80. 22. Kovacs M, Seprodi J, Koppan M, Horvath JE, Vincze B, Teplan I, Flerko B. Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats. J Neuroendocrinol. 2002 Aug;14(8):647-55. 23. Domany B, Koppan M, Bodis J. Results with colposuspension by the Burch procedure in our practice. Am J Obstet Gynecol. 2002 May;186(5):1108. 24. Bódis J, Koppán M, Kornya L, Tinneberg HR, Török A. Influence of melatonin on basal and gonadotropin-stimulated progesterone and estradiol secretion of cultured human granulosa cells and in the superfused granulosa cell system. Gynecol Obstet Invest. 2001;52(3):198-202. 25. Kornya L, Bódis J, Koppán M, Tinneberg HR, Török A. Modulatory effect of acetylcholine on gonadotropin-stimulated human granulosa cell steroid secretion. Gynecol Obstet Invest. 2001;52(2):104-7. 26. Plonowski A, Schally AV, Koppan M, Nagy A, Arencibia JM, Csernus B, Halmos G. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer. 2001 Sep 1;92(5):1168-76. 27. Koppan M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate. 1999 Feb 1;38(2):151-8. 28. Lamharzi N, Schally AV, Koppan M. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept. 1998 Oct 16;77(1-3):185-92. 29. Koppan M, Halmos G, Arencibia JM, Lamharzi N, Schally AV. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer. 1998 Oct 1;83(7):1335-43. 30. Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res. 1998 Sep 15;58(18):4132-7. 31. Lamharzi N, Schally AV, Koppan M, Groot K. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8864-8. 32. Koppán M, Kovács M, Mezö I, Flerkó B. Electrochemical stimulation of the median eminence evokes FSH but not LH release after LHRH antagonist treatment in vivo and in vitro. J Neuroendocrinol. 1998 Mar;10(3):231-6. 33. Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csernus V, Kovács M, Koppán M, Szepesházi K, Kahán Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1794-9. 34. Kovacs M, Schally AV, Nagy A, Koppan M, Groot K. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1420-5. 35. Mező I, Seprődi J, Vincze B, Pályi I, Kéri G, Vadász Z, Tóth G, Kovács M, Koppán M, Horváth JE, Kálnay A, Teplán I. Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity. Biomed Pept Proteins Nucleic Acids. 1996;2(2):33-40. 36. Kovács M, Koppán M, Mezó I, Teplán I. Diverse effects of a potent LH-RH antagonist on the LH and FSH release. Acta Biol Hung. 1994;45(2-4):285-96. 37. Kovács M, Koppán M, Mezö I, Teplán I, Flerkó B. Antiovulatory doses of antagonists of LH-RH inhibit LH and progesterone but not FSH and estradiol release. J Neuroendocrinol. 1993 Dec;5(6):603-8. |
 |
JavaScript DHTML Drop Down Menu By Milonic